세계의 Drug Discovery 기술 시장 보고서(2025년)
Drug Discovery Technologies Global Market Report 2025
상품코드 : 1824374
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

Drug Discovery 기술 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 11.5%를 나타내 1,248억 9,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 유전자 편집용 crispr의 채용, 정밀의료 접근의 확대, 의약품 개발에 있어서의 오믹스 기술의 응용, Drug Discovery에 있어서의 양자 컴퓨팅의 활용, 환자 유래 이종 이식(pdx) 모델의 대두 등에 기인하는 것으로 예측됩니다. 예측 기간의 주요 동향으로는 하이 스루풋 스크리닝의 진보, 자동화된 연구 기기의 개발, 산학 연구의 제휴, 이미징과 현미경의 기술 진보, Drug Discovery에 있어서의 인공지능의 통합, 3D 세포 배양 기술, 약제 설계에 있어서의 머신러닝의 채용, 제약 기업과 하이테크 신흥 기업의 제휴, 데이터 보안을 위한 블록 체인의 통합 등이 있습니다.

향후 5년간의 성장률 11.5%라고 하는 예측은 전회의 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 이스라엘과 프랑스에서 개발된 AI 기반 분자 모델링 소프트웨어와 로봇 분석 시스템의 가격을 올리고 과학적 획기적인 지연을 초래할 수 있기 때문에 미국 연구 기관의 방해가 될 것으로 예측됩니다. 또한 상호관세나 무역마찰·제한의 격화에 의한 세계경제·무역에 대한 악영향에 의해 그 영향은 보다 광범위하게 미칠 것으로 보입니다.

급성질환과 만성질환의 유병률 증가가 예상되기 때문에 Drug Discovery 기술 시장은 장래에 견인역이 될 것입니다. 만성 질환은 1년 이상 지속되어 지속적인 치료가 필요한 질환이지만, Drug Discovery 기술과 의약품 개발의 진보에 의해 수많은 혁신적인 치료가 이루어지고 있습니다. 디지털 헬스툴, 인공지능(AI), 머신러닝 등의 신기술을 의약품 연구개발(R&D) 공정에 도입함으로써 중요한 장벽을 극복하고 유행하는 만성질환의 임상시험을 합리화할 기회가 생깁니다. 유엔(UN)에 따르면 2023년 5월 기준 미국에서는 만성질환이 사망자 10명 중 7명을 차지했고 연간 사망자 수는 170만명을 넘었습니다. 따라서 급성질환과 만성질환의 유병률 상승은 Drug Discovery 기술 시장 원동력이 될 것으로 예측됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Drug discovery technology encompasses a range of techniques and strategies employed in the identification of new drugs and the recognition of chemical entities with potential therapeutic applications. These methodologies are geared towards pinpointing and developing potential drug candidates for the treatment of various diseases.

The primary categories of drug discovery technologies include high-throughput screening, genomics, nanotechnology, bioinformatics, combinational chemistry, pharmacogenomics, biochips, bioanalytical instruments, and ribonucleic acid interface (RNAI). High-throughput screening is a method designed to rapidly assess the biological activity of numerous samples, expediting the drug discovery process. These technologies find application in the discovery of drug types such as small molecule drugs and biologic drugs, addressing conditions such as cancer, immunological disorders, neurological ailments, cardiovascular diseases, and others. Pharmaceutical companies, biopharmaceutical companies, biotechnology firms, research institutes, and other entities utilize these technologies for drug discovery purposes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The drug discovery technologies research report is one of a series of new reports from The Business Research Company that provides drug discovery technologies market statistics, including the drug discovery technologies global market size, regional shares, competitors with a drug discovery technologies market share, detailed drug discovery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery technologies. This drug discovery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The drug discovery technologies market size has grown rapidly in recent years. It will grow from $72.99 billion in 2024 to $80.76 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to growth in genomic and proteomic research, increased understanding of molecular biology, expansion of combinatorial chemistry, adoption of bioinformatics and computational approaches, rise of targeted therapies.

The drug discovery technologies market size is expected to see rapid growth in the next few years. It will grow to $124.89 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to adoption of crispr for gene editing, expansion of precision medicine approaches, application of omics technologies in drug development, utilization of quantum computing in drug discovery, rise of patient-derived xenograft (pdx) models. Major trends in the forecast period include advancements in high-throughput screening, development of automated laboratory equipment, collaboration between academic and industry research, technological advances in imaging and microscopy, integration of artificial intelligence in drug discovery, 3d cell culture technologies, adoption of machine learning in drug design, collaboration between pharma companies and tech startups, integration of blockchain for data security.

The forecast of 11.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. research institutions by raising prices of AI-based molecular modeling software and robotic assay systems developed in Israel and France, potentially delaying scientific breakthroughs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated increase in the prevalence of acute and chronic diseases is poised to drive the drug discovery technologies market in the future. Chronic diseases, which persist for a year or more and necessitate ongoing medical attention, have witnessed numerous innovative treatments through advancements in drug discovery technologies and drug development. The incorporation of emerging technologies such as digital health tools, artificial intelligence (AI), and machine learning in the drug research and development (R&D) process presents opportunities to overcome critical barriers and streamline clinical trials for prevalent chronic diseases. As of May 2023, according to The United Nations (UN), chronic diseases accounted for seven out of 10 deaths in the US, resulting in over 1.7 million annual fatalities. Hence, the escalating prevalence of acute and chronic diseases is expected to be a driving force for the drug discovery technologies market.

The increase in healthcare expenditures is anticipated to propel the growth of the drug discovery technologies market. Healthcare expenditures encompass all costs associated with providing health services, family planning activities, nutrition programs, and emergency assistance with a focus on health. A surge in healthcare spending supports research and development, fostering the expansion of drug discovery technologies through the funding of advanced technologies and infrastructure. For instance, in December 2023, as reported by the Centers for Medicare & Medicaid Services, US healthcare spending witnessed a 4.1% increase in 2022, reaching $4.5 trillion, or $13,493 per person, constituting 17.3% of the country's gross domestic product. Consequently, the rise in healthcare expenditures is a significant driver for the growth of the drug discovery technologies market.

The emergence of advanced technologies stands out as a prominent trend in the drug discovery technologies market. Major companies in this sector are actively introducing sophisticated technologies to maintain their market positions. In May 2023, Google LLC, a US-based technology company, unveiled the Target and Lead Identification Suite-an AI-based tool designed to expedite drug discovery. This tool aids businesses in anticipating and understanding protein structure, a critical element in drug research, by assisting researchers in ingesting, storing, analyzing, and sharing vast volumes of genetic data. The Suite is anticipated to save considerable time and money in the drug development process, addressing a longstanding challenge in the biopharmaceutical sector.

Major companies operating in the drug discovery technologies market are concentrating on advanced solutions, such as drug research and development platforms, to enhance precision in high-throughput analysis. A drug research and development platform serve as a systematic framework for discovering, designing, testing, and bringing pharmaceutical compounds to market. For example, in July 2023, Dotmatics Inc., a US-based scientific software company focused on research and development, launched the Small Molecule Drug Discovery Solution. This comprehensive platform, equipped with pre-configured workflows and enhanced data management features, aims to foster collaboration, boost productivity, streamline operations, and expedite the transformation of data into actionable insights. This advancement accelerates the development of life-enhancing drug therapies by providing researchers with targeted capabilities and templates for a cohesive workspace spanning hit discovery to lead optimization research.

In June 2024, Simulations Plus, Inc., a US-based software company, acquired Pro-ficiency Holdings, Inc. for $100 million. This acquisition allows Simulations Plus to broaden its drug discovery and development capabilities, improving clinical trial operations, commercialization efforts, and data analytics, while also unlocking considerable market growth potential. Pro-ficiency Holdings Inc. is a US-based company that offers simulation-based learning, intelligence, and compliance solutions for life sciences, including technologies for drug discovery.

Major companies operating in the drug discovery technologies market include F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc., Merck KGaA, GE HealthCare Technologies Inc., Agilent Technologies Inc., Dassault Systemes SA, Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Evotec SE, Curia Global Inc., Aragen Life Sciences Private Limited, Luminex Corporation, BioXcel Therapeutics Inc., Certara Inc., Schrodinger Inc., Sygnature Discovery Ltd., Recursion Pharmaceuticals Inc., InSilico Medicine Inc., ChemAxon Ltd., Enamine Ltd., BenevolentAI Limited, OpenEye Scientific Software Inc., Collaborative Drug Discovery Inc., Pharmacelera S.L., Gyros Protein Technologies AB, Optibrium Ltd., Cresset Group, Relay Therapeutics Inc.

North America was the largest region in the drug discovery technologies market in 2024. The regions covered in the drug discovery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the drug discovery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The drug discovery technologies market consists of revenues earned by entities by drug screening, predictive analytics, modeling, simulation, and computational capabilities. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug discovery technologies market also includes sales of automation tools, computational chemistry software, imaging software, and mass spectrometers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Discovery Technologies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drug discovery technologies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for drug discovery technologies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug discovery technologies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Drug Discovery Technologies Market Characteristics

3. Drug Discovery Technologies Market Trends And Strategies

4. Drug Discovery Technologies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Drug Discovery Technologies Growth Analysis And Strategic Analysis Framework

6. Drug Discovery Technologies Market Segmentation

7. Drug Discovery Technologies Market Regional And Country Analysis

8. Asia-Pacific Drug Discovery Technologies Market

9. China Drug Discovery Technologies Market

10. India Drug Discovery Technologies Market

11. Japan Drug Discovery Technologies Market

12. Australia Drug Discovery Technologies Market

13. Indonesia Drug Discovery Technologies Market

14. South Korea Drug Discovery Technologies Market

15. Western Europe Drug Discovery Technologies Market

16. UK Drug Discovery Technologies Market

17. Germany Drug Discovery Technologies Market

18. France Drug Discovery Technologies Market

19. Italy Drug Discovery Technologies Market

20. Spain Drug Discovery Technologies Market

21. Eastern Europe Drug Discovery Technologies Market

22. Russia Drug Discovery Technologies Market

23. North America Drug Discovery Technologies Market

24. USA Drug Discovery Technologies Market

25. Canada Drug Discovery Technologies Market

26. South America Drug Discovery Technologies Market

27. Brazil Drug Discovery Technologies Market

28. Middle East Drug Discovery Technologies Market

29. Africa Drug Discovery Technologies Market

30. Drug Discovery Technologies Market Competitive Landscape And Company Profiles

31. Drug Discovery Technologies Market Other Major And Innovative Companies

32. Global Drug Discovery Technologies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drug Discovery Technologies Market

34. Recent Developments In The Drug Discovery Technologies Market

35. Drug Discovery Technologies Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기